Clinical and Translational Radiation Oncology (Sep 2023)

Initial clinical experience building a dual CT- and MR-guided adaptive radiotherapy program

  • Alex T. Price,
  • Joshua P. Schiff,
  • Eric Laugeman,
  • Borna Maraghechi,
  • Matthew Schmidt,
  • Tong Zhu,
  • Francisco Reynoso,
  • Yao Hao,
  • Taeho Kim,
  • Eric Morris,
  • Xiaodong Zhao,
  • Geoffrey D. Hugo,
  • Gregory Vlacich,
  • Carl J. DeSelm,
  • Pamela P. Samson,
  • Brian C. Baumann,
  • Shahed N. Badiyan,
  • Clifford G. Robinson,
  • Hyun Kim,
  • Lauren E. Henke

Journal volume & issue
Vol. 42
p. 100661

Abstract

Read online

Introduction: Our institution was the first in the world to clinically implement MR-guided adaptive radiotherapy (MRgART) in 2014. In 2021, we installed a CT-guided adaptive radiotherapy (CTgART) unit, becoming one of the first clinics in the world to build a dual-modality ART clinic. Herein we review factors that lead to the development of a high-volume dual-modality ART program and treatment census over an initial, one-year period. Materials and Methods: The clinical adaptive service at our institution is enabled with both MRgART (MRIdian, ViewRay, Inc, Mountain View, CA) and CTgART (ETHOS, Varian Medical Systems, Palo Alto, CA) platforms. We analyzed patient and treatment information including disease sites treated, radiation dose and fractionation, and treatment times for patients on these two platforms. Additionally, we reviewed our institutional workflow for creating, verifying, and implementing a new adaptive workflow on either platform. Results: From October 2021 to September 2022, 256 patients were treated with adaptive intent at our institution, 186 with MRgART and 70 with CTgART. The majority (106/186) of patients treated with MRgART had pancreatic cancer, and the most common sites treated with CTgART were pelvis (23/70) and abdomen (20/70). 93.0% of treatments on the MRgART platform were stereotactic body radiotherapy (SBRT), whereas only 72.9% of treatments on the CTgART platform were SBRT. Abdominal gated cases were allotted a longer time on the CTgART platform compared to the MRgART platform, whereas pelvic cases were allotted a shorter time on the CTgART platform when compared to the MRgART platform. Our adaptive implementation technique has led to six open clinical trials using MRgART and seven using CTgART. Conclusions: We demonstrate the successful development of a dual platform ART program in our clinic. Ongoing efforts are needed to continue the development and integration of ART across platforms and disease sites to maximize access and evidence for this technique worldwide.

Keywords